Published on 7 Mar 2024 on Zacks via Yahoo Finance
MacroGenics (MGNX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -188.46%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.03 per share when it actually produced a loss of $0.52, delivering a surprise of -1,633.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.